{"preliminary_commentary":{"by_channel":{"x_thread":17,"youtube":3,"podcast":2,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07185997\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT07185997","nct_id":"NCT07185997","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07185997. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Firmonertinib 240 mg","type":"EXPERIMENTAL"},{"description":null,"label":"EGFR-TKI inhibitor osimertinib or afatinib based on investigator's choice","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Non-Small-Cell Lung Cancer","Metastatic Non-Small-Cell Lung Cancer","Advanced Non-Small-Cell Lung Cancer","EGFR P-Loop and Alpha C-Helix Compressing","EGFR PACC","EGFR Uncommon Mutations"],"enrollment":{"count":480,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Firmonertinib","otherNames":["AST2818"],"type":"DRUG"},{"name":"EGFR-TKI inhibitor based on investigator's choice","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-14","lead_sponsor":"ArriVent BioPharma, Inc.","official_title":"A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) determined by blinded independent central review (BICR)","timeFrame":"Until progression or death, assessed up to approximately 4 years"},{"measure":"Confirmed overall response rate (ORR) as determined by BICR","timeFrame":"Until progression or death, assessed up to approximately 3 years"}],"references":[],"start_date":{"date":"2025-12-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","url":"https://clinicaltrials.gov/study/NCT07185997"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07185997"}